I hope they don’t pair Leronlimab with the approved drugs for AD, we don’t need the drug associated with the SAE’s of currently approved treatments. The percentage of brain swelling and brain bleeding with attendant mortality to me is unacceptable. There is a focus on backing up the clock to the earlier stages of AD for treatment. I would hope a trial can simply use some of the standardized assessments and hope that investigator initiated trial with 20 patients starts soon. The CCR5 mouse study in AD is quite compelling and OHM20’s take in my opinion is correct, it’s the inflammatory process associated with the amyloid that is the real source of the problem. The quixotic quest to clear amyloid is very misguided IMHO.

Massive unmet need in a horrible and exceptionally costly disease due to the care demands.

This is a good sketch of the assessment landscape for trials:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843702/